(264 days)
Not Found
No
The provided text describes a standard CRRT system and its components, focusing on its intended use and basic functionality. There is no mention of AI, ML, or any related concepts like image processing, training sets, or performance metrics typically associated with AI/ML algorithms.
Yes
The device is intended for use in renal replacement therapies for patients with acute renal failure and/or fluid overload, which are therapeutic interventions.
No
The device is described as a system for continuous renal replacement therapies, which are treatments for renal failure and fluid overload, not for diagnosing conditions.
No
The device description explicitly states that the system consists of a Control Unit, a disposable tubing set (Kit), and an Effluent Bag, all of which are hardware components. The summary also mentions "extensive safety, software, and performance testing," implying hardware and software integration.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for "renal replacement therapies in a hospital or clinical setting where CRRT is administered." This describes a therapeutic treatment performed directly on the patient, not a test performed on a sample taken from the patient.
- Device Description: The description details a system for "continuous renal replacement therapies (hemodialysis, hemofiltration, hemodiafiltration, and ultrafiltration)" for patients with "acute renal failure and/or fluid overload." This further reinforces its role as a treatment device.
- Lack of IVD Characteristics: The description does not mention analyzing biological samples (like blood, urine, or tissue) to provide diagnostic information. It focuses on the process of filtering and managing fluids and solutes in the patient's blood.
IVD devices are designed to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. This device's function is to perform a therapeutic procedure on the patient's blood directly.
N/A
Intended Use / Indications for Use
The Omni System, which consists of the Omni-DL™ Control Unit, Omni-DLTM CVVHDF Kit, and 5 Liter Effluent Bag, is intended for use in renal replacement therapies in a hospital or clinical setting where CRRT is administered. Four different solute and fluid management therapies are available:
- SCUF (Slow Continuous Ultrafiltration)
- CVVH (Continuous Veno-venous Hemofiltration)
- CVVHD (Continuous Veno-venous Hemodialysis)
- CVVHDF (Continuous Veno-venous Hemodiafiltration)
Product codes
KDI
Device Description
The Omni-DLTM System (Omni System) provides continuous renal replacement therapies (hemodialysis, hemofiltration, hemodiafiltration, and ultrafiltration) in an intensive care setting for patients with acute renal failure and/or fluid overload. The Omni System consists of the Omni-DLTM Control Unit (Control Unit), the Omni-DLTM CVVHDF Kit (Omni Kit); a dedicated disposable tubing set which does not incorporate a hemofilter, and a separately packaged 5 Liter Effluent Bag.
The Omni System is a continuous renal replacement therapy (CRRT) system intended for patients with acute renal failure and/or fluid overload. The Omni is indicated for continuous solute and or fluid removal in patients with acute renal failure and/or fluid overload. Blood access for therapy with the Omni System is via established methods of vascular access. The Omni System is designed for use on patients in a hospital setting to provide the following treatments: SCUF (Slow Continuous Ultrafiltration), CVVH (Continuous Veno-Venous Hemofiltration), CVVHD (Continuous Veno-Venous Hemodialysis), and CVVHDF (Continuous Veno-Venous Hemodiafiltration).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
hospital or clinical setting where CRRT is administered, intensive care setting for patients with acute renal failure and/or fluid overload.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical testing was performed on the Omni-DL™ System to demonstrate that the device met its functional and performance specifications. The Omni-DLTM System was subjected to extensive safety, software, and performance testing.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 876.5860 High permeability hemodialysis system.
(a)
Identification. A high permeability hemodialysis system is a device intended for use as an artificial kidney system for the treatment of patients with renal failure, fluid overload, or toxemic conditions by performing such therapies as hemodialysis, hemofiltration, hemoconcentration, and hemodiafiltration. Using a hemodialyzer with a semipermeable membrane that is more permeable to water than the semipermeable membrane of the conventional hemodialysis system (§ 876.5820), the high permeability hemodialysis system removes toxins or excess fluid from the patient's blood using the principles of convection (via a high ultrafiltration rate) and/or diffusion (via a concentration gradient in dialysate). During treatment, blood is circulated from the patient through the hemodialyzer's blood compartment, while the dialysate solution flows countercurrent through the dialysate compartment. In this process, toxins and/or fluid are transferred across the membrane from the blood to the dialysate compartment. The hemodialysis delivery machine controls and monitors the parameters related to this processing, including the rate at which blood and dialysate are pumped through the system, and the rate at which fluid is removed from the patient. The high permeability hemodialysis system consists of the following devices:(1) The hemodialyzer consists of a semipermeable membrane with an in vitro ultrafiltration coefficient (K
uf ) greater than 8 milliliters per hour per conventional millimeter of mercury, as measured with bovine or expired human blood, and is used with either an automated ultrafiltration controller or anther method of ultrafiltration control to prevent fluid imbalance.(2) The hemodialysis delivery machine is similar to the extracorporeal blood system and dialysate delivery system of the hemodialysis system and accessories (§ 876.5820), with the addition of an ultrafiltration controller and mechanisms that monitor and/or control such parameters as fluid balance, dialysate composition, and patient treatment parameters (e.g., blood pressure, hematocrit, urea, etc.).
(3) The high permeability hemodialysis system accessories include, but are not limited to, tubing lines and various treatment related monitors (e.g., dialysate pH, blood pressure, hematocrit, and blood recirculation monitors).
(b)
Classification. Class II. The special controls for this device are FDA's:(1) “Use of International Standard ISO 10993 ‘Biological Evaluation of Medical Device—Part I: Evaluation and Testing,’ ”
(2) “Guidance for the Content of 510(k)s for Conventional and High Permeability Hemodialyzers,”
(3) “Guidance for Industry and CDRH Reviewers on the Content of Premarket Notifications for Hemodialysis Delivery Systems,”
(4) “Guidance for the Content of Premarket Notifications for Water Purification Components and Systems for Hemodialysis,” and
(5) “Guidance for Hemodialyzer Reuse Labeling.”
0
K080650
Page 1 of 3
NOV 2 6 2008
510(k) (Traditional) Submis Section 5, 510(k) Summary
Transvivo
N C O R P O R A T E D
3067 Research Drive Richmond, CA 94806
Summary
This Summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR Part 807.92 for the Omni-DL™ device.
1. Company making the Submission:
| Name: | Transvivo, Inc. |
|---|---|
| Address: | 3067 Research Drive |
| Richmond, CA 94806 USA | |
| Telephone: | 510-223-1054 Voice |
| 510-785-8073 Fax | |
| Contact: | J. Michael Delmage, Ph.D., MBA |
| e-mail: | mdelmage@transvivo.com |
. 2. Device Name:
| Trade/Proprietary Name: | Omni-DL™ |
|---|---|
| Common/Usual Name: | High permeability hemodialysis system |
| Regulation Number: | 876.5860 |
| Product Code: | KDI |
| Review Panel: | Gastroenterology/Urology |
| Third Party Reviewed: | No |
| 513g Number: | C060198 |
3. Predicate Devices:
Omni-DL™ device is substantially equivalent to other Dialyzer High permeability hemodialysis systems in the market such as the Prisma CFM System [K946279].
4. Indications for Use Statement:
Omni-DLTM Control Unit, Omni-DLTM CVVHDF Kit, 5 Liter Effluent Bag
The Omni System, which consists of the Omni-DL™ Control Unit, Omni-DLTM CVVHDF Kit, and 5 Liter Effluent Bag, is intended for use in renal replacement therapies in a hospital or clinical setting where CRRT is administered. Four different solute and fluid management therapies are available:
- SCUF (Slow Continuous Ultrafiltration) .
- CVVH (Continuous Veno-venous Hemofiltration) t
1
KC80650
Page 2 of 3
- ♥ CVVHD (Continuous Veno-venous Hemodialysis)
- . CVVHDF (Continuous Veno-venous Hemodiafiltration)
Description of Device: 5.
The Omni-DLTM System (Omni System) provides continuous renal replacement therapies (hemodialysis, hemofiltration, hemodiafiltration, and ultrafiltration) in an intensive care setting for patients with acute renal failure and/or fluid overload. The Omni System consists of the Omni-DLTM Control Unit (Control Unit), the Omni-DLTM CVVHDF Kit (Omni Kit); a dedicated disposable tubing set which does not incorporate a hemofilter, and a separately packaged 5 Liter Effluent Bag.
The Omni System is a continuous renal replacement therapy (CRRT) system intended for patients with acute renal failure and/or fluid overload. The Omni is indicated for continuous solute and or fluid removal in patients with acute renal failure and/or fluid overload. Blood access for therapy with the Omni System is via established methods of vascular access. The Omni System is designed for use on patients in a hospital setting to provide the following treatments: SCUF (Slow Continuous Ultrafiltration), CVVH (Continuous Veno-Venous Hemofiltration), CVVHD (Continuous Veno-Venous Hemodialysis), and CVVHDF (Continuous Veno-Venous Hemodiafiltration).
Image /page/1/Picture/7 description: The image shows a device with a screen on top and an open compartment below. The screen appears to be blank or displaying a uniform color. The open compartment reveals some internal components, though the details are obscured by shadow. The device has a somewhat boxy shape with rounded edges, and there are some buttons or controls visible on the front panel.
6. Technological Characteristics:
The basic method of construction and materials is very similar. The methods of operation and indications for use are the same for the Omni-DL ™ and the predicate device. Minor modifications were made to the Omni-DLTM System to incorporate current technology.
7. Non-clinical and Clinical Performance Data:
Non-clinical testing was performed on the Omni-DL™ System to demonstrate that the device met its functional and performance specifications. The Omni-DLTM System was subjected to extensive safety, software, and performance testing.
8. Conclusion:
Based on the testing and comparison to the predicate device the Transvivo, Inc., Omni-DLTM System has the same intended use, with similar technological characteristics. Transvivo, Inc., therefore posits that its device is equivalent in safety and effectiveness to the predicate devices.
Summary Section 5 rev2
Delphi Consulting Group
Houston, TX 77071
2
KC80650
Page 3 of 3
510(k) (Traditional) Submission Section 5, 510(k) Summary
Transvivo, Inc.
Q. Michael Dalmayer, M.D., Ph.D.
Michael Dalmayer, Ph.D., M.D.
J. Michael Delmage, Ph President and CEO
Revised per discussion with FDA. Dated: November 24, 2008
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized abstract design resembling an eagle or bird in flight, composed of three curved lines. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" is arranged in a circular fashion around the emblem.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
NOV 2 6 2008
J. Michael Delmage, Ph.D., M.B.A President and CEO Transvivo, Inc. 3067 Research Drive RICHMOND CA 94806
Re: K080650
Trade/Device Name: Omni-DL™ Control Unit, Omni-DL™ CVVHDF Kit, 5 Liter Effluent Bag Regulation Number: 21 CFR §876.5860 Regulation Name: High permeability hemodialysis system Regulatory Class: II Product Code: KDI Dated: October 27, 2008 Received: October 29, 2008
Dear Dr. Delmage:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
4
Page 2
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:
| 21 CFR 876.xxx | (Gastroenterology/Renal/Urology | 240-276-011. |
|---|---|---|
| 21 CFR 884.xxx | (Obstetrics/Gynecology) | 240-276-011. |
| 21 CFR 894.xxx | (Radiology) | 240-276-012 |
| Other | 240-276-010- |
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometrics' (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Joppu M. Whang
Joyce M. Whang, Ph.D. Acting Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Indications for Use Statement
510(k) Number : K 80650
Device Name: Omni-DLTM Control Unit, Omni-DL™ CVVHDF Kit, 5 Liter Effluent Bag
The Omni System, which consists of the Omni-DL™ Control Unit, Omni-DL™ CVVHDF Kit, and 5 Liter Effluent Bag, is intended for use in renal replacement therapies in a hospital or clinical setting whee CRRT is administered. Four different solute and fluid management therapies are valiable
- SCUF (Slow Continuous Ultrafiltration) .
- CVVH (Continuous Veno-venous Hemofiltration) D
- CVVHD (Continuous Veno-venous Hemodialysis) .
- CVVHDF (Continuous Veno-venous Hemodiafiltration) .
Prescription Use YES (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off)
Division of Reproductive, Abdominal and
Radiological Devices
2_Indications_for_Use Rev.2 phi Consulting Group
510(k) Number